{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-066006","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-10-15T20:26:10+00:00","discovered_at":"2026-10-15T20:27:00.195884+00:00","generated_at":"2026-10-15T20:27:12.608383+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Crescent Biopharma updates pipeline: CR-001 ASCEND combo cohorts enrolling; CR-002 IND cleared","bullets":["ASCEND Phase 1/2 trial of CR-001 (PD-1 x VEGF bispecific) completed monotherapy dose escalation; initial data expected Q1 2027, including ORR in up to 12 1L NSCLC patients and data from >125 patients.","Chemo combo expansion cohorts enrolling in ASCEND; initial data mid-2027 across 1L NSCLC, 1L pMMR/MSS CRC, 3L CRC, 1L biliary, 1L pMMR endometrial, and gastric/GEJ cancers.","Partner Kelun-Biotech runs China trials of CR-001 (SKB118) plus TROP2 ADC sac-TMT: Phase 2 NSCLC data mid-2027; Phase 2 EGFR-mutant NSCLC initiating; Phase 1/2 with CR-003 (SKB105) to start H1 2027.","CR-002 (PD-L1 topoisomerase inhibitor ADC) received FDA IND allowance in Oct 2026; global Phase 1/2 APOLLO trial to start Q4 2026 in advanced solid tumors, initial data H2 2027.","Kelun-Biotech granted Crescent exclusive rights to CR-003 (SKB105), an integrin-beta 6 ADC, for US, Europe and markets outside Greater China; China Phase 1/2 proof-of-concept data expected Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-066006","json":"https://secwatch.observer/filing/0001628280-26-066006.json","markdown":"https://secwatch.observer/filing/0001628280-26-066006.md","text":"https://secwatch.observer/filing/0001628280-26-066006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/0001628280-26-066006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-15T20:27:12.608383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}